Last updated 2026-06-18
Total raised
—
Stage
Pre-Funding
Founded
2023
Headcount
4
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
ReadeRx is developing small molecule inhibitors targeting the RNA binding protein IGF2BP1 as a novel treatment for cancer. IGF2BP1 is an oncofetal RNA binding protein expressed in many types of cancers. it regulates RNA function at many levels, including intracellular RNA localization, RNA stability, and translational control. IGFB2P1 is widely expressed in development but is dramatically reduced in normal mature tissues. In many cancers IFG2BP1 is reactivated, assuming a pivotal role in stabilizing key pro-oncogenic RNAs, thereby promoting pro-oncogenic and pro-tumorigenic processes. Consequently, the inhibition of IGF2BP1 emerges as a highly promising strategy for cancer therapy.
Q&A
- What is ReadeRx Therapeutics' primary focus?
- ReadeRx Therapeutics is developing small molecule inhibitors targeting the RNA binding protein IGF2BP1 as a novel treatment for cancer, focusing on RNA-based cancer therapeutics.
- When was ReadeRx Therapeutics founded?
- ReadeRx Therapeutics was founded in January 2023.
- What is the current status of ReadeRx Therapeutics?
- ReadeRx Therapeutics is currently non-active, and as of July 2026, it ceased to operate.
- How many employees does ReadeRx Therapeutics have?
- ReadeRx Therapeutics has 1-10 employees.
- What is ReadeRx Therapeutics' current funding stage?
- ReadeRx Therapeutics is in the Pre-Funding stage.
- Where is ReadeRx Therapeutics headquartered?
- ReadeRx Therapeutics is headquartered in Tel Aviv-Yafo, Israel.
- What is the product stage of ReadeRx Therapeutics?
- The product stage of ReadeRx Therapeutics is R&D.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
oncologypharmaceuticalscancer-therapycancer
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2023-1 |
|---|---|
| Employees (exact) | 4 |